Literature DB >> 12643760

Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules.

Masanori Onda1, James J Vincent, Byungkook Lee, Ira Pastan.   

Abstract

Chemical modification of proteins with substances such as poly(ethylene glycol) can add useful properties to proteins. Currently PEGylation is done in a random manner utilizing amino residues dispersed throughout a protein. For proteins such as immunotoxins, which have several different functional domains, random modification leads to inactivation. To determine if we could produce an immunotoxin with a diminished number of lysine residues so that chemical modification could be restricted to certain regions of the protein, we chose the recombinant immunotoxin anti-Tac(dsFv)-PE38 that has 13 lysine residues in the Fv portion and 3 in the toxin. We prepared a series of mutants with 0-12 lysines in the Fv and 0 or 3 in the toxin. Almost all of these molecules retain full biological activity. Our data indicate that replacement of lysine residues can be achieve without loss of biological potency. These molecules are a useful starting point to carry out site-specific PEGylation experiments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643760     DOI: 10.1021/bc020069r

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  5 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Podocyte injury damages other podocytes.

Authors:  Taiji Matsusaka; Eric Sandgren; Ayumi Shintani; Valentina Kon; Ira Pastan; Agnes B Fogo; Iekuni Ichikawa
Journal:  J Am Soc Nephrol       Date:  2011-06-30       Impact factor: 10.121

Review 3.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

4.  EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.

Authors:  Hidenobu Ochiai; Gary E Archer; James E Herndon; Chien-Tsun Kuan; Duane A Mitchell; Darell D Bigner; Ira H Pastan; John H Sampson
Journal:  Cancer Immunol Immunother       Date:  2007-07-19       Impact factor: 6.968

5.  Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach.

Authors:  Asami Ueda; Mitsuo Umetsu; Takeshi Nakanishi; Kentaro Hashikami; Hikaru Nakazawa; Shuhei Hattori; Ryutaro Asano; Izumi Kumagai
Journal:  Int J Mol Sci       Date:  2020-01-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.